Interferon-γ Is Increased in Patients with Primary Sjogren's Syndrome and Raynaud's Phenomenon

Seminars in Arthritis and Rheumatism

Volumn 39, Issue 3, 2009, Pages 197-202

  Willeke, Peter ^a   Schlüter, Bernhard ^a   Schotte, Heiko ^a   Domschke, Wolfram ^a   Gaubitz, Markus ^a   Becker, Heidemarie ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

interferon ; leukopenia; Raynaud's phenomenon; Sjogren's syndrome; T cell activation

Indexed keywords

AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CD45RO ANTIGEN; CD69 ANTIGEN; COMPLEMENT COMPONENT C3C; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA INTERFERON; HYDROXYCHLOROQUINE; INTERLEUKIN 2 RECEPTOR ALPHA; MYCOPHENOLIC ACID;

ADULT; AGED; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ECHOGRAPHY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FINGER; FLOW CYTOMETRY; HUMAN; IMMUNOPATHOLOGY; LEUKOPENIA; MALE; NON INVASIVE PROCEDURE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SJOEGREN SYNDROME; SKIN COLOR; THYROIDITIS; VASOSPASM;

ADULT; AGED; CASE-CONTROL STUDIES; COMPLEMENT C3; FEMALE; HLA-DR3 ANTIGEN; HLA-DR4 ANTIGEN; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; PREVALENCE; RAYNAUD DISEASE; RISK FACTORS; SJOGREN'S SYNDROME; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 70449624163     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2008.04.002     Document Type: Article

References (42)

1. Skopouli F.N., Dafni U., Ioannidis J.P., and Moutsopoulos H.M. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthritis Rheum 29 (2000) 296-304
2. Garcia-Carrasco M., Siso A., Ramos-Casals M., Rosas J., de la Red G., and Gil V. Raynaud's phenomenon in primary Sjogren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol 29 (2002) 726-730
3. Skopouli F.N., Talal A., Galanopoulou V., Tsampoulas C.G., Drosos A.A., and Moutsopoulos H.M. Raynaud's phenomenon in primary Sjogren's syndrome. J Rheumatol 17 (1990) 618-620
4. Cooke J.P., and Marshall J.M. Mechanisms of Raynaud's disease. Vasc Med 10 (2005) 293-307
5. Gerli R., Muscat C., Giansanti M., Danieli M.G., Sciuto M., Gabrielli A., et al. Quantitative assessment of salivary gland inflammatory infiltration in primary Sjogren's syndrome: its relationship to different demographic, clinical and serological features of the disorder. Br J Rheumatol 36 (1997) 969-975
6. Vitali C., Tavoni A., Viegi G., Begliomini E., Agnesi A., and Bombardieri S. Lung involvement in Sjogren's syndrome: a comparison between patients with primary and with secondary syndrome. Ann Rheum Dis 44 (1985) 455-461
7. Ramos M., Cervera R., Garcia-Carrasco M., Miret C., Munoz F.J., Espinosa G., et al. Primary Sjogren's syndrome: clinical and immunologic study of 80 patients. Med Clin (Barc) 108 (1997) 652-657
8. Molteni M., Della B.S., Mascagni B., Bazzi S., Zulian C., Compasso S., et al. Increased interferon-gamma (IFN-gamma) levels produced in vitro by alloactivated T lymphocytes in systemic sclerosis and Raynaud's phenomenon. Clin Exp Immunol 116 (1999) 164-168
9. Schapira D., Nahir A.M., and Hadad N. Interferon-induced Raynaud's syndrome. Semin Arthritis Rheum 32 (2002) 157-162
10. Hagiwara E., Gourley M.F., Lee S., and Klinman D.K. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 39 (1996) 379-385
11. Vitali C., Bombardieri S., Jonsson R., Moutsopoulos H.M., Alexander E.L., Carsons S.E., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61 (2002) 554-558
12. Brennan P., Silman A., Black C., Bernstein R., Coppock J., Maddison P., et al. Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The UK Scleroderma Study Group. Br J Rheumatol 32 (1993) 357-361
13. Bartelink M.L., Wollersheim H., Leesmans E., de B.T., and Thien T. A standardized finger cooling test for Raynaud's phenomenon: diagnostic value and sex differences. Eur Heart J 14 (1993) 614-622
14. Assmann G., and Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 70 (1992) 733-737
15. Czerkinsky C., Andersson G., Ekre H.P., Nilsson L.A., Klareskog L., and Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods 110 (1988) 29-36
16. Willeke P., Schotte H., Schlüter B., Erren M., Becker H., Dyong A., et al. Interleukin 1beta and tumour necrosis factor alpha secreting cells are increased in the peripheral blood of patients with primary Sjogren's syndrome. Ann Rheum Dis 62 (2003) 359-362
17. Vaquerano J.E., Peng M., Chang J.W., Zhou Y.M., and Leong S.P. Digital quantification of the enzyme-linked immunospot (ELISPOT). Biotechniques 25 (1998) 830-834 836.
18. Willeke P., Schluter B., Schotte H., Erren M., Mickholz E., Domschke W., et al. Increased frequency of GM-CSF secreting PBMC in patients with active systemic lupus erythematosus can be reduced by immunoadsorption. Lupus 13 (2004) 257-262
19. Kraus A., Caballero-Uribe C., Jakez J., Villa A.R., and Alarcon-Segovia D. Raynaud's phenomenon in primary Sjogren's syndrome. Association with other extraglandular manifestations. J Rheumatol 19 (1992) 1572-1574
20. Youinou P., Pennec Y.L., Katsikis P., Jouquan J., Fauquert P., and Le G.P. Raynaud's phenomenon in primary Sjogren's syndrome. Br J Rheumatol 29 (1990) 205-207
21. Kruit W.H., Eggermont A.M., and Stoter G. Interferon-alpha induced Raynaud's syndrome. Ann Oncol 11 (2000) 1501-1502
22. Blaheta R.A., Scholz M., Hailer N.P., Bereiter-Hahn J., Encke A., and Markus B.H. Adhesion and penetration properties of human lymphocytes acting on allogeneic vascular endothelial cells. Immunology 81 (1994) 538-545
23. Cozzolino F., Torcia M., Lucibello M., Morbidelli L., Ziche M., Platt J., et al. Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. J Clin Invest 91 (1993) 2504-2512
24. Ronnblom L.E., Alm G.V., and Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 30 (1991) 537-540
25. Lamas S., Michel T., Collins T., Brenner B.M., and Marsden P.A. Effects of interferon-gamma on nitric oxide synthase activity and endothelin-1 production by vascular endothelial cells. J Clin Invest 90 (1992) 879-887
26. Sun D., Emmert-Buck M.R., and Fox P.C. Differential cytokine mRNA expression in human labial minor salivary glands in primary Sjogren's syndrome. Autoimmunity 28 (1998) 125-137
27. Cha S., Brayer J., Gao J., Brown V., Killedar S., Yasunari U., et al. A dual role for interferon-gamma in the pathogenesis of Sjogren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand J Immunol 60 (2004) 552-565
28. Ogawa N., Ping L., Zhenjun L., Takada Y., and Sugai S. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjogren's syndrome. Arthritis Rheum 46 (2002) 2730-2741
29. Valesini G., Priori R., Borsetti A., Tiberti A., Moncada A., and Pivetti-Pezzi P. Clinical serological correlations in the evaluation of Sjogren's syndrome. Clin Exp Rheumatol 7 (1989) 197-202
30. Villarreal G.M., Alcocer-Varela J., and Llorente L. Cytokine gene and CD25 antigen expression by peripheral blood T cells from patients with primary Sjogren's syndrome. Autoimmunity 20 (1995) 223-229
31. Ramos-Casals M., Cervera R., Garcia-Carrasco M., Vidal J., Trejo O., Jimenez S., et al. Cytopenia and past human parvovirus B19 infection in patients with primary Sjogren's syndrome. Semin Arthritis Rheum 29 (2000) 373-378
32. Pontikoglou C., Liapakis G., Pyrovolaki K., Papadakis M., Bux J., Eliopoulos G.D., et al. Evidence for downregulation of erythropoietin receptor in bone marrow erythroid cells of patients with chronic idiopathic neutropenia. Exp Hematol 34 (2006) 1312-1322
33. Papadaki H.A., Stamatopoulos K., Damianaki A., Gemetzi C., Anagnostopoulos A., Papadaki T., et al. Activated T-lymphocytes with myelosuppressive properties in patients with chronic idiopathic neutropenia. Br J Haematol 128 (2005) 863-876
34. Biro E., Szekanecz Z., Czirjak L., Danko K., Kiss E., Szabo N.A., et al. Association of systemic and thyroid autoimmune diseases. Clin Rheumatol 25 (2006) 240-245
35. Jara L.J., Navarro C., Brito-Zeron M.P., Garcia-Carrasco M., Escarcega R.O., and Ramos-Casals M. Thyroid disease in Sjogren's syndrome. Clin Rheumatol 26 (2007) 1601-1606
36. Shagan B.P., and Friedman S.A. Raynaud's phenomenon and thyroid deficiency. Arch Intern Med 140 (1980) 832-833
37. Lateiwish A.M., Feher J., Baraczka K., Racz K., Kiss R., and Glaz E. Remission of Raynaud's phenomenon after L-thyroxine therapy in a patient with hypothyroidism. J Endocrinol Invest 15 (1992) 49-51
38. Brito-Zeron P., Ramos-Casals M., Bove A., Sentis J., and Font J. Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. Rheumatology (Oxford) 46 (2007) 1359-1362
39. Valter I., and Maricq H.R. Prevalence of Raynaud's phenomenon in 2 ethnic groups in the general population of Estonia. J Rheumatol 25 (1998) 697-702
40. Foster H., Kelly C., and Griffiths I. Raynaud's phenomenon and primary Sjogren's syndrome. Br J Rheumatol 29 (1990) 493-494
41. Gottenberg J.E., Busson M., Loiseau P., Cohen-Solal J., Lepage V., Charron D., et al. In primary Sjogren's syndrome. HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum 48 (2003) 2240-2245
42. Mann D.L., and Moutsopoulos H.M. HLA DR alloantigens in different subsets of patients with Sjogren's syndrome and in family members. Ann Rheum Dis 42 (1983) 533-536